(Recorded live on Tuesday, July 14, 2020) Biomarkers are important tools for successful biopharmaceutical-targeted drug development and regulatory approval. Biomarkers can be diagnostic and/or prognostic, indicative of precision drug targeting. As such, biomarkers are...
(Recorded live on Thursday, April 16, 2020) Image analysis of histological tissue sections is a fast-growing field that is becoming widely accepted as a research tool for scientists and pathologists, providing quantitative, reproducible data in lieu of varying manual...
Flagship was a virtual exhibitor this year during the AACR Virtual Meeting II. Our scientists, led by Chuck Caldwell, shared a new poster during the virtual event.
EXHIBITING – BOOTH #802 AT MOLECULAR MED TRI-CON 2020March 1-4, 2020 Moscone Center, San Francisco, CA Visit our booth to learn about Flagship’s services that bring efficiencies and accuracy to clinical development by changing the paradigm of traditional pathology,...
Recruiting/Exhibiting – 5th Annual Life Science Industry ShowcaseFebruary 19, 2020 Aurora, CO Visit Flagship at our table at this networking event, which connects Colorado biotech, pharmaceutical, medical device, and diagnostic companies with students from Colorado...
EXHIBITING – THE 5TH ANNUAL MARKETSANDMARKETS BIOMARKER AND COMPANION DIAGNOSTICS CONFERENCEFebruary 6-7, 2020 San Diego, CA Visit us at the show in San Diego to meet several of Flagship’s leaders in science and business and to discuss your biomarker and tissue data...
Sign up to receive industry and company news, including The Cut Point, Flagship’s quarterly e-newsletter.
NEWS
IntroductionThe success of clinical trials is highly dependent on the intricacies of patient recruitment. Other challenges, from the costs of clinical supplies to the specific procedural requirements that can extend physicians’ time, can increase costs. There are also...
Broomfield, CO – June 1, 2021 – Flagship Biosciences, the leader in data-centric pathology and tissue analysis, today announced that the company has moved its headquarters to a new location in Broomfield, Colorado, just north of Denver. The office, at 11800 Ridge...
Cambridge, MA and Westminster, CO — May 12, 2021 — Leap Therapeutics (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, and Flagship Biosciences, the leader in data-centric pathology and tissue analysis, today...
PUBLICATIONS/POSTERS
Key Takeaways Successful pathology AI does not replace, but assist pathologists in high-complexity tissue analysis Transparency and control is retained in a pathologist-centric AI-based system Pathology AI enables cost effective healthcare by testing for multiple...
Key takeaways Building Predictive Models of Clinical Outcomes in Immune Oncology Using Computational Tissue Analysis Scorecards The spatial location of PD-L1 expression can identify patients who will likely respond to anti-PD-1/PD-L1 therapy Flagship’s unique spatial...
Artificial intelligence (AI) systems for pathology may appear to compete with manual pathology, as they enable the assessment of thousands of cells and application of complex scoring schemes beyond the capacity of a human pathologist. However, this technology...